nimodipine has been researched along with Vertigo in 8 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
Vertigo: An illusion of movement, either of the external world revolving around the individual or of the individual revolving in space. Vertigo may be associated with disorders of the inner ear (EAR, INNER); VESTIBULAR NERVE; BRAINSTEM; or CEREBRAL CORTEX. Lesions in the TEMPORAL LOBE and PARIETAL LOBE may be associated with FOCAL SEIZURES that may feature vertigo as an ictal manifestation. (From Adams et al., Principles of Neurology, 6th ed, pp300-1)
| Excerpt | Relevance | Reference |
|---|---|---|
| "There were two formulations used to assess the effectiveness in vertigo treatment from peripheral origin: nimodipine administrated three times daily (Nimotop®) 30 mg versus nimodipine AP administrated once daily (Tropocer®) 90 mg; both of them in a administrated in a prospective, randomized, double-blind, double dummy, multicenter and parallel-group study, where patients with peripheral vertigo defined as a score ≥7 on the Vertigo-Dizziness Differential Diagnosis Score were included." | 9.17 | Evaluation of the effect of nimodipine o.d. (extended release) vs nimodipine t.i.d. in the treatment of peripheral vertigo. ( Alejandro, R; Carlos, RJ; Consuelo, P; Elena, C; Glenda, C; Lisbeth, M; Maria, GY, 2013) |
| "There were two formulations used to assess the effectiveness in vertigo treatment from peripheral origin: nimodipine administrated three times daily (Nimotop®) 30 mg versus nimodipine AP administrated once daily (Tropocer®) 90 mg; both of them in a administrated in a prospective, randomized, double-blind, double dummy, multicenter and parallel-group study, where patients with peripheral vertigo defined as a score ≥7 on the Vertigo-Dizziness Differential Diagnosis Score were included." | 5.17 | Evaluation of the effect of nimodipine o.d. (extended release) vs nimodipine t.i.d. in the treatment of peripheral vertigo. ( Alejandro, R; Carlos, RJ; Consuelo, P; Elena, C; Glenda, C; Lisbeth, M; Maria, GY, 2013) |
| "Eighty-three patients with CCI were randomly divided into YXQNG and nimodipine (ND) groups, the score of vertigo and the change in cerebral blood velocity before and after treatment were observed." | 5.11 | Study on Yangxue Qingnao granule in treating chronic cerebrovascular insufficiency. ( Cai, DF; Chen, YP; Gu, XX; Teng, Y; Wen, M; Yang, YK, 2005) |
| "Two calcium antagonists were used to treat vertigo (nimodipine, 89 patients; cinnarizine, 92 patients), and all patients were maintained on the same dosage regimen until they completed 12 weeks of treatment." | 5.10 | New approaches to the management of peripheral vertigo: efficacy and safety of two calcium antagonists in a 12-week, multinational, double-blind study. ( Abiuso, J; Alegría, J; Arenas, JE; Castañeda, JR; F, GV; Flaskamp, R; Gómez, JM; González, RH; Guerra, OJ; Hanuch, E; Hernández, J; Hidalgo, LO; Madrid, CE; Martínez, C; Morán, LM; Pedraza, A; Pianese, CP; Ponce, JE; Quijano, D; Ramírez, AM; Rubio, AT; Sanjuán, AP; Uribe, JO; Volpi, C, 2002) |
| "Due to its proposed vasoactive and neuroprotective effects, nimodipine may play a role in the treatment of a number of otolaryngic pathologies including VS, Ménière's disease, peripheral vertigo, RLN injury, and facial weakness after maxillofacial surgery." | 4.98 | Nimodipine for the treatment of otolaryngic indications. ( Levy, ZD; Shafeeq, H; Sin, JH, 2018) |
| "An animal experimental model of vertebrobasilar insufficiency was developed." | 2.66 | Calcium entry blockers in the treatment of vertebrobasilar insufficiency. ( Hofferberth, B, 1986) |
| "Vertebrobasilar insufficiency (VBI) is a clinical syndrome which includes different transient brain stem symptoms." | 2.65 | [Calcium blockers in the therapy of vertebrobasilar insufficiency. Results of animal experiments and clinical studies]. ( Hofferberth, B, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sin, JH | 1 |
| Shafeeq, H | 1 |
| Levy, ZD | 1 |
| Wu, C | 1 |
| Liao, L | 1 |
| Yan, X | 1 |
| Li, M | 1 |
| Wu, S | 1 |
| Wang, J | 1 |
| Lin, J | 1 |
| Li, S | 1 |
| Gao, L | 1 |
| DU, J | 1 |
| Yang, R | 1 |
| Lisbeth, M | 1 |
| Consuelo, P | 1 |
| Glenda, C | 1 |
| Elena, C | 1 |
| Carlos, RJ | 1 |
| Alejandro, R | 1 |
| Maria, GY | 1 |
| Monzani, D | 1 |
| Genovese, E | 1 |
| Pini, LA | 1 |
| Di Berardino, F | 1 |
| Alicandri Ciufelli, M | 1 |
| Galeazzi, GM | 1 |
| Presutti, L | 1 |
| Gu, XX | 1 |
| Cai, DF | 1 |
| Yang, YK | 1 |
| Teng, Y | 1 |
| Chen, YP | 1 |
| Wen, M | 1 |
| Hofferberth, B | 2 |
| Pianese, CP | 1 |
| Hidalgo, LO | 1 |
| González, RH | 1 |
| Madrid, CE | 1 |
| Ponce, JE | 1 |
| Ramírez, AM | 1 |
| Morán, LM | 1 |
| Arenas, JE | 1 |
| Rubio, AT | 1 |
| Uribe, JO | 1 |
| Abiuso, J | 1 |
| Hanuch, E | 1 |
| Alegría, J | 1 |
| Volpi, C | 1 |
| Flaskamp, R | 1 |
| Sanjuán, AP | 1 |
| Gómez, JM | 1 |
| Hernández, J | 1 |
| Pedraza, A | 1 |
| Quijano, D | 1 |
| Martínez, C | 1 |
| Castañeda, JR | 1 |
| Guerra, OJ | 1 |
| F, GV | 1 |
2 reviews available for nimodipine and Vertigo
| Article | Year |
|---|---|
Nimodipine for the treatment of otolaryngic indications.
Topics: Calcium Channel Blockers; Humans; Meniere Disease; Neuroprotective Agents; Nimodipine; Otorhinolaryn | 2018 |
Nimodipine in otolaryngology: from past evidence to clinical perspectives.
Topics: Calcium Channel Blockers; Humans; Migraine Disorders; Nimodipine; Otorhinolaryngologic Diseases; Ver | 2015 |
6 trials available for nimodipine and Vertigo
| Article | Year |
|---|---|
Effects of Yangxue Qingnao Granules on chronic cerebral circulation insufficiency: a randomized, double-blind, double-dummy, controlled multicentre trial.
Topics: Adult; Cerebrovascular Circulation; China; Dizziness; Dose-Response Relationship, Drug; Double-Blind | 2013 |
Evaluation of the effect of nimodipine o.d. (extended release) vs nimodipine t.i.d. in the treatment of peripheral vertigo.
Topics: Adult; Aged; Aged, 80 and over; Calcium Channel Blockers; Delayed-Action Preparations; Double-Blind | 2013 |
Study on Yangxue Qingnao granule in treating chronic cerebrovascular insufficiency.
Topics: Aged; Aged, 80 and over; Animals; Blood Flow Velocity; Cerebrovascular Circulation; Cerebrovascular | 2005 |
[Calcium blockers in the therapy of vertebrobasilar insufficiency. Results of animal experiments and clinical studies].
Topics: Animals; Calcium Channel Blockers; Cerebrovascular Circulation; Cinnarizine; Clinical Trials as Topi | 1984 |
New approaches to the management of peripheral vertigo: efficacy and safety of two calcium antagonists in a 12-week, multinational, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Calcium Channel Blockers; Cinnarizine; Drug Administration Schedule; | 2002 |
Calcium entry blockers in the treatment of vertebrobasilar insufficiency.
Topics: Animals; Clinical Trials as Topic; Dogs; Flunarizine; Humans; Nimodipine; Nystagmus, Pathologic; Pen | 1986 |